CARLSBAD, Calif., Oct. 15 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (Nasdaq: IMNR) today announced the appointment of Michael K.
Green, CPA, as Vice President, Finance and Chief Financial Officer of the
Company.  Mr. Green has extensive finance, business, and accounting experience
from his work in the biotechnology and technology sectors in the United States
and Australia, with special expertise in financings, mergers and acquisitions,
licensing, and SEC matters.  He previously served as Senior Vice President,
Finance and CFO for Synbiotics Corporation, a publicly-traded animal health
diagnostic company, and Immunopharmaceutics, Inc., a venture funded company.
Michael Jeub, the Company's former Vice President of Finance and CFO, resigned
to seek other opportunities.
    Mr. Green is joining The Immune Response Corporation as the Company
continues to strengthen its financial position and advance the clinical
development of REMUNE(R), an immune-based therapeutic vaccine being evaluated
in Phase II clinical studies for treatment of HIV, the virus that causes AIDS.
    "With the completion of the Company's recent private placement financing,
I am looking forward to managing the continued funding of several key ongoing
projects, including the Phase II clinical trials and the development of a new
vaccine with potential prophylactic and therapeutic applications for HIV.  I
am excited about participating in the development of potential therapies to
treat the devastating HIV epidemic," Mr. Green stated.
    "Mike Green is a proven financial and business executive with a
comprehensive background in accounting systems, internal controls, and
financial management of biotech manufacturing facilities," said John N.
Bonfiglio, Ph.D., CEO of The Immune Response Corporation.  "He will be
responsible for managing expenses, day-to-day financial operations, and
participating in our financing activities.  In addition, Mike will help
represent the Company in the investor relations area."
    Mr. Green has been a frequent speaker on Sarbanes-Oxley and corporate
governance issues.  He is active with several professional organizations, and
was the former San Diego chapter president of the National Association of
Accountants.

    About The Immune Response Corporation and REMUNE(R)
    The Immune Response Corporation is a biopharmaceutical company dedicated
to treating and preventing HIV and AIDS through the development of
immune-based therapeutic vaccines such as REMUNE, its lead product candidate.
The Company was co-founded by medical pioneer Dr. Jonas Salk, who was
instrumental in the formulation of REMUNE, which is currently in Phase II
clinical development.
    HIV, the human immunodeficiency virus, is the virus that causes AIDS, a
condition that slowly destroys the body's immune system, making it vulnerable
to infections.  REMUNE is designed to induce a specific immune response to the
HIV virus.  It is comprised of HIV-1 virus that has been chemically killed and
inactivated so that it is non-infectious, plus an adjuvant that helps enhance
the body's immune response to the virus.  More than 60 million people have
been infected with HIV since it was first recognized in 1981, and
approximately 40 million people around the world are living with HIV today.

    This news release contains forward-looking statements.  Actual results
could vary materially from those expected due to a variety of risk factors,
including whether the Company will continue as a going concern and
successfully raise proceeds from financing activities sufficient to fund
operations and additional clinical trials of REMUNE, the uncertainty of
successful completion of any such clinical trials, whether REMUNE will be
effective as either a preventive or therapeutic vaccine, whether future trials
will be conducted and whether the results of such trials will coincide with
the results of REMUNE in preclinical trials.  These risks, among others, are
set forth in The Immune Response Corporation's SEC filings including, but not
limited to, its Annual Report on Form 10-K for the year ended
December 31, 2002, and subsequent Quarterly Reports on Form 10-Q.  The Company
undertakes no obligation to publicly release the results of any revisions to
these forward-looking statements, which may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

    REMUNE(R) is a registered trademark of The Immune Response Corporation.

                   For further information please contact:
                       The Immune Response Corporation
          (Investors) - Kathy Lane, (760) 771-2236 or info@imnr.com
 (Media) - Gwen Rosenberg, Rosenberg Business Communications, (858) 759-0759

Link to this page: